Sigmanomics
Back to all insights

Important Alert for Investors of Applied Therapeutics Inc: Know Your Rights and Seek Justice with Levi Korsinsky

Important Alert for Investors of Applied Therapeutics Inc: Know Your Rights and Seek Justice with Levi Korsinsky

Investigation of Applied Therapeutics, Inc. by Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. (“Applied Therapeutics, Inc.”) (NASDAQ:APLT) concerning possible violations of federal securities laws.

Applied Therapeutics issued a press release on November 27, 2024, announcing “that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.”

Effect on Investors

As an investor in Applied Therapeutics Inc., it is crucial to understand your rights and seek justice in case of any violations of federal securities laws. The investigation initiated by Levi & Korsinsky aims to protect the interests of investors and ensure transparency in the company’s operations. It is essential to stay informed and be proactive in safeguarding your investments.

Effect on the World

The FDA’s issuance of a Complete Response Letter for govorestat raises concerns about the potential impact on the treatment of Classic Galactosemia. This development may affect patients awaiting new treatment options and the healthcare industry as a whole. It is important to monitor further updates from Applied Therapeutics Inc. regarding their drug application process and seek clarity on the implications of this regulatory action.

Conclusion

In conclusion, investors of Applied Therapeutics Inc. should be aware of the investigation by Levi & Korsinsky and stay informed about developments related to the company’s drug application for govorestat. Seeking justice and understanding your rights as an investor is key to protecting your interests in the stock market. Stay informed, seek guidance, and make informed decisions in light of this important alert.

more insights

“Navigating the Storm: Ethereum’s Struggle with Leadership and Market Demand”

January 24, 2025

Ethereum’s Uncertain Path Forward Challenges Facing the Ethereum Foundation Ethereum’s path forward is becoming increasingly uncertain, with growing calls for leadership reform to address significant governance challenges. The Ethereum Foundation, the organization responsible for overseeing the development of the Ethereum platform, is facing internal pressure and external market shifts that

Read more >

“Unlocking the Potential: How Algorand’s New Staking Rewards Could Ignite a Surge in ALGO Price!”

January 24, 2025

Algorand Introduces New Staking Rewards Program Enhancing Incentives for Validators Algorand, a proof-of-stake blockchain network, has recently announced the launch of a new staking rewards program. This initiative aims to further incentivize validators on the platform, ultimately strengthening the network’s security and efficiency. Evolution of Consensus Mechanism This development comes

Read more >
Sigmanomics

Menu

About

News

Signals

Risk Disclaimer: Sigmanomics is a financial portal that provides news and analysis about the different financial markets. The articles that we serve on the portal depend solely on the opinion and analysis of our economists which in no way are intended to incite a visitor of the website or an investor to trade or sell/buy a certain instrument. It is the responsibility of the visitor / trader only to evaluate his trading strategies and whether he is capable of trading with taking into consideration that losing all the capital invested is a possibility. The visitor should seek an independent professional financial advisor to discuss his or her trading strategies. Moreover, the provided rates for the different instruments are indicative only and cannot be used for trading purposes. Therefore, no responsibility can be imposed on sigmanomics.com.com and the company operating the portal for any loss of money that may occur to the visitor by using the website.